Articles liés à The Biotech CEO’s Guide to Your First FDA Meeting
Synopsis
Your first FDA meeting could shape the future of your entire development program.
But many biotech teams prepare for it as a regulatory event rather than a strategic decision point.
They focus on the meeting request, briefing package, questions, and presentation—without first agreeing on what the company needs to learn, which decisions FDA’s feedback must inform, or how the program will respond if the agency takes a different view.
The Biotech CEO’s Guide to Your First FDA Meeting offers a practical, executive-level framework for preparing more strategically.
Written by Nilou Sarah Arden, PhD—a former FDA regulator and global biopharma regulatory leader—the guide helps biotech founders, CEOs, executives, and development teams look beyond the mechanics of the meeting and ask a more important question:
What must this FDA interaction enable us to decide?
Inside, you will learn how to:
• Define the decisions for which your company needs FDA input
• Identify the most consequential uncertainties in your development plan
• Prioritize questions that could materially change the program
• Distinguish evidence, assumptions, beliefs, and unresolved uncertainty
• Integrate CMC, nonclinical, clinical, and regulatory strategies
• Recognize which questions should not be asked—or should not be asked yet
• Build a briefing package that supports clear, decision-useful feedback
• Prepare for disagreement, conditional advice, and unexpected responses
• Decide which commitments should be made now and which can wait
• Align the leadership team before entering the meeting
The guide also includes:
• A one-page FDA meeting strategy
• A five-minute strategic-readiness diagnostic
• A CEO checklist for final preparation
• A post-meeting framework for turning regulatory feedback into decisions, actions, and organizational learning
This is not a technical manual for writing an FDA briefing package. It is a field guide for leading the decisions around one.
Whether your company is preparing for a pre-IND meeting, an initial regulatory interaction, or another consequential FDA milestone, this guide will help you connect regulatory strategy to the wider development pathway—including evidence, manufacturing, clinical planning, capital, sequencing, risk, and future options.
Because a successful FDA meeting is not simply one that goes smoothly.
It is one that helps the company make better decisions.
Part of the Cambase Executive Field Guides series: practical intelligence for the decisions shaping the path from science to patients.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Résultats de recherche pour The Biotech CEO’s Guide to Your First FDA Meeting
Image d'archives
The Biotech CEO's Guide to Your First FDA Meeting (Cambase Executive Field Guides)
impression à la demandeVendeur : California Books, Miami, FL, Etats-Unis
Évaluation du vendeur 4 sur 5 étoiles
Etat : New. Print on Demand. N° de réf. du vendeur I-9798171207274
Acheter neuf
EUR 19
Livraison gratuite
Expédition nationale : Etats-Unis
Expédition nationale : Etats-Unis
Quantité disponible : Plus de 20 disponibles
Image d'archives
The Biotech CEO's Guide to Your First FDA Meeting (Paperback)
impression à la demandeVendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Évaluation du vendeur 5 sur 5 étoiles
Paperback. Etat : new. Paperback. Your first FDA meeting could shape the future of your entire development program.But many biotech teams prepare for it as a regulatory event rather than a strategic decision point.They focus on the meeting request, briefing package, questions, and presentation-without first agreeing on what the company needs to learn, which decisions FDA's feedback must inform, or how the program will respond if the agency takes a different view.The Biotech CEO's Guide to Your First FDA Meeting offers a practical, executive-level framework for preparing more strategically.Written by Nilou Sarah Arden, PhD-a former FDA regulator and global biopharma regulatory leader-the guide helps biotech founders, CEOs, executives, and development teams look beyond the mechanics of the meeting and ask a more important question: What must this FDA interaction enable us to decide?Inside, you will learn how to: - Define the decisions for which your company needs FDA input- Identify the most consequential uncertainties in your development plan- Prioritize questions that could materially change the program- Distinguish evidence, assumptions, beliefs, and unresolved uncertainty- Integrate CMC, nonclinical, clinical, and regulatory strategies- Recognize which questions should not be asked-or should not be asked yet- Build a briefing package that supports clear, decision-useful feedback- Prepare for disagreement, conditional advice, and unexpected responses- Decide which commitments should be made now and which can wait- Align the leadership team before entering the meetingThe guide also includes: - A one-page FDA meeting strategy- A five-minute strategic-readiness diagnostic- A CEO checklist for final preparation- A post-meeting framework for turning regulatory feedback into decisions, actions, and organizational learningThis is not a technical manual for writing an FDA briefing package. It is a field guide for leading the decisions around one.Whether your company is preparing for a pre-IND meeting, an initial regulatory interaction, or another consequential FDA milestone, this guide will help you connect regulatory strategy to the wider development pathway-including evidence, manufacturing, clinical planning, capital, sequencing, risk, and future options.Because a successful FDA meeting is not simply one that goes smoothly.It is one that helps the company make better decisions.Part of the Cambase Executive Field Guides series: practical intelligence for the decisions shaping the path from science to patients. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9798171207274
Acheter neuf
EUR 19,03
Livraison gratuite
Expédition nationale : Etats-Unis
Expédition nationale : Etats-Unis
Quantité disponible : 1 disponible(s)
Image d'archives
The Biotech CEO's Guide to Your First FDA Meeting
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
PAP. Etat : New. New Book. Shipped from UK. Established seller since 2000. N° de réf. du vendeur L2-9798171207274
Acheter neuf
EUR 18,94
Expédition à EUR 3,83
Expédition depuis Royaume-Uni vers Etats-Unis
Expédition depuis Royaume-Uni vers Etats-Unis
Quantité disponible : Plus de 20 disponibles
Image fournie par le vendeur
The Biotech CEO's Guide to Your First FDA Meeting
Edité par
Createspace Independent Publishing Platform Sep 2026, 2026
ISBN 13 : 9798171207274
Neuf
Taschenbuch
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Taschenbuch. Etat : Neu. Neuware - Your first FDA meeting could shape the future of your entire development program.But many biotech teams prepare for it as a regulatory event rather than a strategic decision point.They focus on the meeting request, briefing package, questions, and presentation-without first agreeing on what the company needs to learn, which decisions FDA's feedback must inform, or how the program will respond if the agency takes a different view.The Biotech CEO's Guide to Your First FDA Meeting offers a practical, executive-level framework for preparing more strategically.Written by Nilou Sarah Arden, PhD-a former FDA regulator and global biopharma regulatory leader-the guide helps biotech founders, CEOs, executives, and development teams look beyond the mechanics of the meeting and ask a more important question: What must this FDA interaction enable us to decide Inside, you will learn how to: - Define the decisions for which your company needs FDA input- Identify the most consequential uncertainties in your development plan- Prioritize questions that could materially change the program- Distinguish evidence, assumptions, beliefs, and unresolved uncertainty- Integrate CMC, nonclinical, clinical, and regulatory strategies- Recognize which questions should not be asked-or should not be asked yet- Build a briefing package that supports clear, decision-useful feedback- Prepare for disagreement, conditional advice, and unexpected responses- Decide which commitments should be made now and which can wait- Align the leadership team before entering the meetingThe guide also includes: - A one-page FDA meeting strategy- A five-minute strategic-readiness diagnostic- A CEO checklist for final preparation- A post-meeting framework for turning regulatory feedback into decisions, actions, and organizational learningThis is not a technical manual for writing an FDA briefing package. It is a field guide for leading the decisions around one.Whether your company is preparing for a pre-IND meeting, an initial regulatory interaction, or another consequential FDA milestone, this guide will help you connect regulatory strategy to the wider development pathway-including evidence, manufacturing, clinical planning, capital, sequencing, risk, and future options.Because a successful FDA meeting is not simply one that goes smoothly.It is one that helps the company make better decisions.Part of the Cambase Executive Field Guides series: practical intelligence for the decisions shaping the path from science to patients. N° de réf. du vendeur 9798171207274
Acheter neuf
EUR 28,71
Expédition à EUR 35
Expédition depuis Allemagne vers Etats-Unis
Expédition depuis Allemagne vers Etats-Unis
Quantité disponible : 2 disponible(s)
Image d'archives
The Biotech CEO's Guide to Your First FDA Meeting (Paperback)
impression à la demandeVendeur : CitiRetail, Stevenage, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
Paperback. Etat : new. Paperback. Your first FDA meeting could shape the future of your entire development program.But many biotech teams prepare for it as a regulatory event rather than a strategic decision point.They focus on the meeting request, briefing package, questions, and presentation-without first agreeing on what the company needs to learn, which decisions FDA's feedback must inform, or how the program will respond if the agency takes a different view.The Biotech CEO's Guide to Your First FDA Meeting offers a practical, executive-level framework for preparing more strategically.Written by Nilou Sarah Arden, PhD-a former FDA regulator and global biopharma regulatory leader-the guide helps biotech founders, CEOs, executives, and development teams look beyond the mechanics of the meeting and ask a more important question: What must this FDA interaction enable us to decide?Inside, you will learn how to: - Define the decisions for which your company needs FDA input- Identify the most consequential uncertainties in your development plan- Prioritize questions that could materially change the program- Distinguish evidence, assumptions, beliefs, and unresolved uncertainty- Integrate CMC, nonclinical, clinical, and regulatory strategies- Recognize which questions should not be asked-or should not be asked yet- Build a briefing package that supports clear, decision-useful feedback- Prepare for disagreement, conditional advice, and unexpected responses- Decide which commitments should be made now and which can wait- Align the leadership team before entering the meetingThe guide also includes: - A one-page FDA meeting strategy- A five-minute strategic-readiness diagnostic- A CEO checklist for final preparation- A post-meeting framework for turning regulatory feedback into decisions, actions, and organizational learningThis is not a technical manual for writing an FDA briefing package. It is a field guide for leading the decisions around one.Whether your company is preparing for a pre-IND meeting, an initial regulatory interaction, or another consequential FDA milestone, this guide will help you connect regulatory strategy to the wider development pathway-including evidence, manufacturing, clinical planning, capital, sequencing, risk, and future options.Because a successful FDA meeting is not simply one that goes smoothly.It is one that helps the company make better decisions.Part of the Cambase Executive Field Guides series: practical intelligence for the decisions shaping the path from science to patients. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. N° de réf. du vendeur 9798171207274
Acheter neuf
EUR 23,34
Expédition à EUR 43,04
Expédition depuis Royaume-Uni vers Etats-Unis
Expédition depuis Royaume-Uni vers Etats-Unis
Quantité disponible : 1 disponible(s)